The ALZT-QoL and M1 (muscarinic) reversible acetylcholine estarse inhibitor drug candidates are compounds designed to improve the Quality of Life for mild-to-moderate Alzheimer’s patients. We are approaching this by developing drugs that act on specific brain receptors to compensate for the decreased neuronal firing caused by amyloid-beta peptides and amyloid plaques. People with higher plaque burden, but who exhibit high brain activity, manifest Alzheimer’s disease at a slower rate compared to people with high plaque burden and lower brain activity. The binding of ALZT-QoL drugs to their receptors supports higher brain activity, which is intended to translate to slower disease progression. We are developing these drugs for treatment of patients with higher plaque burden in mild-to-moderate Alzheimer’s disease.